Vincent Launay-Vacher

Vincent Launay-Vacher

Auto-generated profile, based on publicly available information

Vincent Launay-Vacher

Service ICAR, Pitié-Salpêtrière University Hospital, Paris, France

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2007 in Cancer
Verified
Journal Article
Open access
PDF file
VLVincent Launay‐Vacher
Vincent Launay‐Vacher
SOStéphane Oudard
Stéphane Oudard
NJNicolas Janus
Nicolas Janus
JGJoseph Gligorov
Joseph Gligorov
XPXavier Pourrat
Xavier Pourrat
OGOn behalf of the Renal Insufficiency and Cancer Medications (IRMA) Study Group
On behalf of the Renal Insufficiency and Cancer Medications (IRMA) Study Group
BACKGROUND.: The Renal Insufficiency and Cancer Medications (IRMA) study is a French national observational study. The results from this study of nearly 5000 patients demonstrated the high prevalence of renal impairment in a population of patients with solid tumors.METHODS.: Every cancer patient who presented at oncology departments that participated in the study over at least 1 of 2 predefined periods during 2004 were included. Renal function was calculated using Cockcroft‐Gault and abbreviated Modification of Diet in Renal Disease (aMDRD) formulae to estimate the prevalence of renal insufficiency (RI) according to the Kidney Disease Outcomes Quality Initiative‐Kidney Disease Improving Global Outcomes definition and stratification. Anticancer drugs were studied with regard to their potential renal toxicity and dosage adjustment.RESULTS.: Of the 4684 patients from the 15 centers, 7.2% had serum creatinine levels >110 μmol/L. However, when they were assessed using Cockcroft‐Gault and aMDRD formulae, 57.4% and 52.9% of patients had abnormal renal function or RI, respectively. Of the 7181 anticancer drug prescriptions, 53.4% required dose adjustments for RI. Of the patients treated, 79.9% received at least 1 such drug. And 80.1% received potentially nephrotoxic drugs.CONCLUSIONS.: RI was common in patients with cancer, and drug dosage adjustments often were necessary. Renal function should be evaluated in all cancer patients using either the Cockcroft‐Gault formula or the aMDRD formula, including patients with normal serum creatinine levels. In patients who are at high risk for drug toxicity, the dosage should be adapted to renal function, and the use of nephrotoxic therapies should be avoided whenever possible. Cancer 2007. © 2007 American Cancer Society.

1 May 2005 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
HIHassane Izzedine
Hassane Izzedine
VLVincent Launay-Vacher
Vincent Launay-Vacher
GDGilbert Deray
Gilbert Deray

12 January 2017 in American Journal of Nephrology
Verified
Journal Article
Closed access
RWRimda Wanchoo
Rimda Wanchoo
SKSabine Karam
Sabine Karam
NUNupur N. Uppal
Nupur N. Uppal
VBValerie S. Barta
Valerie S. Barta
GDGilbert Deray
Gilbert Deray
OIon behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors
on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors
Background: Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has revolutionized the treatment of malignancies by engaging the patient's own immune system against the tumor rather than targeting the cancer directly. These therapies have demonstrated a significant benefit in the treatment of melanomas and other cancers. Summary: In order to provide an extensive overview of the renal toxicities induced by these agents, a Medline search was conducted of published literature related to ipilimumab-, pembrolizumab-, and nivolumab-induced kidney toxicity. In addition, primary data from the initial clinical trials of these agents and the FDA adverse reporting system database were also reviewed to determine renal adverse events. Acute interstitial nephritis (AIN), podocytopathy, and hyponatremia were toxicities caused by ipilimumab. The main adverse effect associated with both the PD-1 inhibitors was AIN. The onset of kidney injury seen with PD-1 inhibitors is usually late (3-10 months) compared to CTLA-4 antagonists related renal injury, which happens earlier (2-3 months). PD-1 as opposed to CTLA-4 inhibitors has been associated with kidney rejection in transplantation. Steroids appear to be effective in treating the immune-related adverse effects noted with these agents. Key Message: Although initially thought to be rare, the incidence rates of renal toxicities might be higher (9.9-29%) as identified by recent studies. As a result, obtaining knowledge about renal toxicities of immune checkpoint inhibitors is extremely important.

4 March 2008 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
VLVincent Launay-Vacher
Vincent Launay-Vacher
JRJean-Baptiste Rey
Jean-Baptiste Rey
CBCorinne isnard bagnis
Corinne isnard bagnis
GDGilbert Deray
Gilbert Deray
MDMikael Daouphars
Mikael Daouphars

1 February 2003 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
HIHassane Izzedine
Hassane Izzedine
VLVincent Launay-Vacher
Vincent Launay-Vacher
CBCorinne isnard bagnis
Corinne isnard bagnis
GDGilbert Deray
Gilbert Deray

1 January 2007 in European Journal of Cancer
Verified
Journal Article
Closed access
SLStuart M. Lichtman
Stuart M. Lichtman
HWHans Wildiers
Hans Wildiers
VLVincent Launay-Vacher
Vincent Launay-Vacher
CSChristopher Steer
Christopher Steer
ÉCétienne Chatelut
étienne Chatelut
MAMatti Aapro
Matti Aapro